Literature DB >> 20880394

Differential effects of uridine adenosine tetraphosphate on purinoceptors in the rat isolated perfused kidney.

Markus Tölle1, Mirjam Schuchardt, Annette Wiedon, Tao Huang, Lars Klöckel, Joachim Jankowski, Vera Jankowski, Walter Zidek, Markus van der Giet.   

Abstract

BACKGROUND AND
PURPOSE: Purinergic signalling plays an important role in vascular tone regulation in humans. We have identified uridine adenosine tetraphosphate (Up(4)A) as a novel and highly potent endothelial-derived contracting factor. Up(4)A induces strong vasoconstrictive effects in the renal vascular system mainly by P2X(1) receptor activation. However, other purinoceptors are also involved and were analysed here. EXPERIMENTAL APPROACH: The rat isolated perfused kidney was used to characterize vasoactive actions of Up(4)A. KEY
RESULTS: After desensitization of the P2X(1) receptor by α,β-methylene ATP (α,β-meATP), Up(4)A showed dose-dependent P2Y(2)-mediated vasoconstriction. Continuous perfusion with Up(4)A evoked a biphasic vasoconstrictor effect: there was a strong and rapidly desensitizing vasoconstriction, inhibited by P2X(1) receptor desensitization. In addition, there is a long-lasting P2Y(2)-mediated vasoconstriction. This vasoconstriction could be blocked by suramin, but not by PPADS or reactive blue 2. In preparations of the rat isolated perfused kidney model with an elevated vascular tone, bolus application of Up(4)A showed a dose-dependent vasoconstriction that was followed by a dose-dependent vasodilation. The vasoconstriction was in part sensitive to P2X(1) receptor desensitization by α,β-meATP, and the remaining P2Y(2)-mediated vasoconstriction was only inhibited by suramin. The Up(4)A-induced vasodilation depended on activation of nitric oxide synthases, and was mediated by P2Y(1) and P2Y(2) receptor activation. CONCLUSIONS AND IMPLICATIONS: Up(4)A activated P2X(1) and P2Y(2) receptors to act as a vasoconstrictor, whereas endothelium-dependent vasodilation was induced by P2Y(1/2) receptor activation. Up(4)A might be of relevance in the physiology and pathophysiology of vascular tone regulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20880394      PMCID: PMC2990153          DOI: 10.1111/j.1476-5381.2010.00914.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  The Role of P2Y Receptors in the Control of Blood Pressure.

Authors:  Markus Van Der Giet; Gunter Giebing; Markus Tolle; Sven Schmidt
Journal:  Drug News Perspect       Date:  2002-12

2.  The pattern of distribution of selected ATP-sensitive P2 receptor subtypes in normal rat kidney: an immunohistological study.

Authors:  C M Turner; O Vonend; C Chan; G Burnstock; R J Unwin
Journal:  Cells Tissues Organs       Date:  2003       Impact factor: 2.481

3.  Vasomotor activity of diadenosine triphosphate and diadenosine tetraphosphate in isolated arteries.

Authors:  R Busse; A Ogilvie; U Pohl
Journal:  Am J Physiol       Date:  1988-05

4.  Conversion of angiotensin I into angiotensin II in the isolated perfused rat kidney.

Authors:  K G Hofbauer; H Zschiedrich; W Rauh; F Gross
Journal:  Clin Sci       Date:  1973-05       Impact factor: 6.124

5.  In vivo effects of diadenosine polyphosphates on rat renal microcirculation.

Authors:  G Gabriëls; K Endlich; K H Rahn; E Schlatter; M Steinhausen
Journal:  Kidney Int       Date:  2000-06       Impact factor: 10.612

6.  Reduced atherosclerotic lesions in P2Y1/apolipoprotein E double-knockout mice: the contribution of non-hematopoietic-derived P2Y1 receptors.

Authors:  Béatrice Hechler; Monique Freund; Catherine Ravanat; Stéphanie Magnenat; Jean-Pierre Cazenave; Christian Gachet
Journal:  Circulation       Date:  2008-07-28       Impact factor: 29.690

7.  Mechanism of purinergic activation of endothelial nitric oxide synthase in endothelial cells.

Authors:  Cleide Gonçalves da Silva; Anke Specht; Barbara Wegiel; Christiane Ferran; Elzbieta Kaczmarek
Journal:  Circulation       Date:  2009-02-02       Impact factor: 29.690

8.  Effects of dinucleoside polyphosphates on regulation of coronary vascular tone.

Authors:  Markus van der Giet; Sven Schmidt; Markus Tölle; Joachim Jankowski; Hartmut Schlüter; Walter Zidek; Martin Tepel
Journal:  Eur J Pharmacol       Date:  2002-07-19       Impact factor: 4.432

9.  Increased uridine adenosine tetraphosphate concentrations in plasma of juvenile hypertensives.

Authors:  Vera Jankowski; Andreas-Alexander Meyer; Peter Schlattmann; Yu Gui; Xi-long Zheng; Irini Stamcou; Kristina Radtke; Thi Nguyet Anh Tran; Markus van der Giet; Markus Tölle; Walter Zidek; Joachim Jankowski
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-06-14       Impact factor: 8.311

10.  Diadenosine phosphates and the physiological control of blood pressure.

Authors:  H Schlüter; E Offers; G Brüggemann; M van der Giet; M Tepel; E Nordhoff; M Karas; C Spieker; H Witzel; W Zidek
Journal:  Nature       Date:  1994-01-13       Impact factor: 49.962

View more
  20 in total

1.  Alterations in vasoconstrictor responses to the endothelium-derived contracting factor uridine adenosine tetraphosphate are region specific in DOCA-salt hypertensive rats.

Authors:  Takayuki Matsumoto; Rita C Tostes; R Clinton Webb
Journal:  Pharmacol Res       Date:  2011-09-14       Impact factor: 7.658

2.  Control of vascular tone by purines and pyrimidines.

Authors:  Geoffrey Burnstock
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  P2Y₂ receptor activation decreases blood pressure and increases renal Na⁺ excretion.

Authors:  Timo Rieg; Maria Gerasimova; José L Boyer; Paul A Insel; Volker Vallon
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-05-25       Impact factor: 3.619

Review 4.  Constrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetes.

Authors:  Takayuki Matsumoto; Styliani Goulopoulou; Kumiko Taguchi; Rita C Tostes; Tsuneo Kobayashi
Journal:  Br J Pharmacol       Date:  2015-07-08       Impact factor: 8.739

5.  The endothelium-derived contracting factor uridine adenosine tetraphosphate induces P2Y(2)-mediated pro-inflammatory signaling by monocyte chemoattractant protein-1 formation.

Authors:  Mirjam Schuchardt; Jasmin Prüfer; Nicole Prüfer; Annette Wiedon; Tao Huang; Miriam Chebli; Vera Jankowski; Joachim Jankowski; Monika Schäfer-Korting; Walter Zidek; Markus van der Giet; Markus Tölle
Journal:  J Mol Med (Berl)       Date:  2011-04-13       Impact factor: 4.599

6.  Uridine adenosine tetraphosphate is a novel neurogenic P2Y1 receptor activator in the gut.

Authors:  Leonie Durnin; Sung Jin Hwang; Masaaki Kurahashi; Bernard T Drumm; Sean M Ward; Kent C Sasse; Kenton M Sanders; Violeta N Mutafova-Yambolieva
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-23       Impact factor: 11.205

Review 7.  Uridine adenosine tetraphosphate and purinergic signaling in cardiovascular system: An update.

Authors:  Zhichao Zhou; Takayuki Matsumoto; Vera Jankowski; John Pernow; S Jamal Mustafa; Dirk J Duncker; Daphne Merkus
Journal:  Pharmacol Res       Date:  2018-12-13       Impact factor: 7.658

8.  Mechanisms underlying uridine adenosine tetraphosphate-induced vascular contraction in mouse aorta: Role of thromboxane and purinergic receptors.

Authors:  Zhichao Zhou; Changyan Sun; Stephen L Tilley; S Jamal Mustafa
Journal:  Vascul Pharmacol       Date:  2015-04-25       Impact factor: 5.773

9.  Enhanced uridine adenosine tetraphosphate-induced contraction in renal artery from type 2 diabetic Goto-Kakizaki rats due to activated cyclooxygenase/thromboxane receptor axis.

Authors:  Takayuki Matsumoto; Shun Watanabe; Ryusuke Kawamura; Kumiko Taguchi; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2013-07-31       Impact factor: 3.657

10.  Uridine adenosine tetraphosphate-induced contraction is increased in renal but not pulmonary arteries from DOCA-salt hypertensive rats.

Authors:  Takayuki Matsumoto; Rita C Tostes; R Clinton Webb
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-06       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.